Journal
JOURNAL OF HEADACHE AND PAIN
Volume 17, Issue -, Pages -Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1186/s10194-016-0654-5
Keywords
Complete Freund's Adjuvant; Dura mater; Trigeminal ganglion; pERK1/2; IL-1 beta; KYNA
Categories
Funding
- Swedish Medical Research Council [5889, TAMOP-4.2.2A-11/1KONV-2012-0052]
- Hungarian Brain Research Programme (NAP) [KTIA_13_NAP-A-III/9]
- EUROHEADPAIN (FP7-Health Innovation) [602633]
- MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences
- University of Szeged
Ask authors/readers for more resources
Background: Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue (SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic inflammatory response in the trigeminal ganglion. Methods: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1 beta expression in V1 region of the trigeminal ganglion were investigated using immunohistochemistry and Western blot. Findings: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and IL-1 beta activation in the trigeminal ganglion. No significant change was noted in case of repeated treatment with SZR72 as compared to a single dose. Conclusions: This is the first study that demonstrates that one dose of KYNA analog before application of CFA can give anti-inflammatory response in a model of trigeminal activation, opening a new line for further investigations regarding possible effects of KYNA derivates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available